Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Bellerophon Therapeutics, Inc. (BLPH)

0.9   -0.043 (-4.56%) 06-06 16:00
Open: 0.9163 Pre. Close: 0.943
High: 1.04 Low: 0.8769
Volume: 3,347,491 Market Cap: 9(M)

Technical analysis

as of: 2023-06-06 3:48:03 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 8.43     One year: 13.02
Support: Support1: 0.87    Support2: 0.72
Resistance: Resistance1: 7.22    Resistance2: 11.14
Pivot: 6.99
Moving Average: MA(5): 4.54     MA(20): 7.43
MA(100): 5.89     MA(250): 3.07
MACD: MACD(12,26): -1.4     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 3.6     %D(3): 5.6
RSI: RSI(14): 19.7
52-week: High: 12.57  Low: 0.67
Average Vol(K): 3-Month: 478 (K)  10-Days: 1,655 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ BLPH ] has closed below the lower bollinger band by 7.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 176.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.34 - 1.35 1.35 - 1.36
Low: 0.87 - 0.88 0.88 - 0.89
Close: 0.93 - 0.94 0.94 - 0.95

Company Description

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Headline News

Tue, 06 Jun 2023
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails - Nasdaq

Tue, 06 Jun 2023
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails - Yahoo Finance

Mon, 05 Jun 2023
Dow Drops Over 100 Points; Crude Oil Rises - Chemours (NYSE:CC), Bellerophon Therapeutics (NASDAQ:BLPH) - Benzinga

Mon, 05 Jun 2023
Healthcare Stocks on the Move Monday: TMBR, MGRX, SCLX, ABEO, BLPH, CSTL, MNK, PDSB - InvestorsObserver

Mon, 05 Jun 2023
Nasdaq Rises 70 Points; ISM Services PMI Drops In May - Bellerophon Therapeutics (NASDAQ:BLPH), Circor In - Benzinga

Mon, 05 Jun 2023
US Stocks Mixed; SAIC Posts Upbeat Results - Bellerophon Therapeutics (NASDAQ:BLPH), Aemetis (NASDAQ:AMTX - Benzinga

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 10 (M)
Shares Float 7 (M)
% Held by Insiders 4.1 (%)
% Held by Institutions 44.4 (%)
Shares Short 240 (K)
Shares Short P.Month 435 (K)

Stock Financials

EPS -1.2
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1
Profit Margin (%) -201.6
Operating Margin (%) -270.8
Return on Assets (ttm) -50.7
Return on Equity (ttm) -85
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0.53
EBITDA (p.s.) -1.46
Qtrly Earnings Growth 0
Operating Cash Flow -10 (M)
Levered Free Cash Flow -8 (M)

Stock Valuations

PE Ratio -0.77
PEG Ratio -0.1
Price to Book value 0.89
Price to Sales 1.67
Price to Cash Flow -0.97

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.